Beckman Coulter, Inc. (BEC) Announces the Creation of Beckman Coulter Genomics
BEVERLY, Mass., Aug. 12 -- Beckman Coulter, Inc. (NYSE: BEC - News) today announced the creation of Beckman Coulter Genomics. The new company, which combines Agencourt Bioscience and the newly acquired Cogenics, offers researchers a single genomic services resource with expanded global capabilities.
"Through the creation of Beckman Coulter Genomics, we have successfully brought together the industry's leading genomic service providers to offer our customers the highest-quality data and analysis," said Richard Creager, Ph.D., Beckman Coulter group vice president of Immunoassay, Molecular Diagnostics and Genomic Services.
Genomic researchers dedicate months to collecting DNA and RNA samples. Before turning over precious samples for analysis, they need to be able to trust that their service provider understands the research goals and will deliver a successful outcome. From classic to cutting-edge, Beckman Coulter Genomics' team has expertise and experience on a wide range of genomic technology platforms and is dedicated to delivering the highest-quality results. Services currently available through Beckman Coulter Genomics include sequencing, sample preparation, genotyping, gene expression, biological efficiency and safety testing, with support for all levels of regulatory compliance, including Clinical Laboratory Improvement Amendments (CLIA). In addition, Beckman Coulter Genomics offers all three commercially available next-generation sequencing platforms: Roche 454 Genome Sequencer FLX with Titanium, Applied Biosystems SOLiD* and Illumina* Genome Analyzer.
"We understand that each customer, each sample and each study is unique and extremely important," said Susan Evans, Ph.D., general manager of Beckman Coulter Genomics. "That is why we strive to create a partnership with each customer through a consistent and personalized approach. Our experienced team has the energy and resolve needed to deliver high-quality results scientists can trust, on time and on budget."
Beckman Coulter Genomics has offices throughout North America and Europe. For more information about Beckman Coulter Genomics and its services please visit: www.beckmangenomics.com, www.agencourt.com and www.cogenics.com. For more information about Beckman Coulter, please visit www.beckmancoulter.com.
Beckman Coulter and the stylized logo are registered trademarks of Beckman Coulter, Inc.
*Trademarks are property of their respective owners.
About Beckman Coulter Genomics
Beckman Coulter Genomics, headquartered in Beverly, Massachusetts, is a leading provider of genomic services and nucleic acid purification products, serving life-science researchers and the pharmaceutical industry throughout the world. The company was created by combining Beckman Coulter's Agencourt Bioscience with the newly acquired Cogenics. By providing technical expertise, combined with personalized service, Beckman Coulter Genomics delivers the highest-quality data, robust analyses and innovative thinking. For more information, visit www.beckmangenomics.com, www.agencourt.com or www.cogenics.com.
About Beckman Coulter
Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of supplies, test kits, service and operating-type lease payments, represents approximately 78 percent of the company's 2008 annual revenue of $3.1 billion. For more information, visit www.beckmancoulter.com.
Link to the news release at: http://www.beckman.com/HR/PressRoom/oc_pressReleases_detail.asp?Key=XXXX